Showing 654 results

Filters Content type: News, Editors' picks, About HIV Topic: New & experimental hepatitis C treatment

News and information about clinical trials and regulatory approval of new medications to treat hepatitis C.

New & experimental hepatitis C treatment

Two new hepatitis C therapies fast-tracked in Europe

Editor's pick
PMLive
25 January 2017
New & experimental hepatitis C treatment

Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) for Chronic Hepatitis C Achieved High SVR12 Rates in Genotype 1 Japanese Patients

Editor's pick
AbbVIe press release
9 January 2017
New & experimental hepatitis C treatment

Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen’s Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV

Editor's pick
Achillion press release
26 September 2016
New & experimental hepatitis C treatment

Achillion Announces 100% SVR Reported in Janssen’s Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCV

Editor's pick
Achillion press release
9 September 2016
Hepatitis C treatment

Sofosbuvir/velpatasvir shows high cure rate in HIV/HCV co-infection study

News
21 July 2016
New & experimental HIV treatments

Treatment Action Group: Pipeline Report 2016

Editor's pick
Treatment Action Group
15 July 2016
New & experimental hepatitis C treatment

European Commission Grants Marketing Authorization for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C

Editor's pick
Gilead press release
8 July 2016
New & experimental hepatitis C treatment

FDA places RG-101 for HCV on clinical hold

Editor's pick
Healio
5 July 2016
New & experimental hepatitis C treatment

FDA Approves Gilead's Epclusa Combo Pill for All Hepatitis C Genotypes

Editor's pick
HIVandHepatitis.com
4 July 2016
New & experimental hepatitis C treatment

Merck Receives Positive CHMP Opinion for ZEPATIER™ (elbasvir and grazoprevir) in the European Union

Editor's pick
MSD press release
30 May 2016
New & experimental hepatitis C treatment

European CHMP Adopts Positive Opinion for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C

Editor's pick
Gilled press relase
27 May 2016
Hepatitis C treatment

WHO issues new hepatitis C guidelines, EASL guidelines update forthcoming in September

News
12 May 2016
Hepatitis C treatment

Portugal's roll-out of HCV therapy with DAAs achieves impressive results

News
27 April 2016
Hepatitis C treatment

DAAs achieve excellent outcomes in real-world settings

News
21 April 2016
New & experimental hepatitis C treatment

Sofosbuvir/velpatasvir + GS-9857 works well for treatment-experienced hepatitis C patients

News
15 April 2016
New & experimental hepatitis C treatment

Ravidasvir plus sofosbuvir demonstrates high cure rate for people with hepatitis C genotype 4

News
8 March 2016
New & experimental hepatitis C treatment

Fair Pricing Coalition Recognizes Merck’s Lower Price for Curative Hepatitis C Treatment, Calls for Manufacturers to Reduce Excessive Prices and Increase Patient Assistance

Editor's pick
Fair Pricing Coalition
8 February 2016
New & experimental hepatitis C treatment

U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C

Editor's pick
Bristol-Myers Squibb press release
8 February 2016
Pharmaceutical industry

Merck Throws a Wrench in Drug Pricing

Editor's pick
Bloomberg
1 February 2016
New & experimental hepatitis C treatment

New Merck combination pill Zepatier approved for hepatitis C treatment in the United States

News
1 February 2016
New & experimental hepatitis C treatment

Zepatier for hepatitis C approved in Canada

Editor's pick
CATIE
1 February 2016
New & experimental hepatitis C treatment

Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults

Editor's pick
Merck press release
29 January 2016
New & experimental hepatitis C treatment

The 2016 Hepatitis C Drug Approval Outlook

Editor's pick
Poz
18 January 2016
New & experimental hepatitis C treatment

AbbVie Initiates Enrollment of Six Global Phase 3 Clinical Studies for Once-Daily, Pan-Genotypic Hepatitis C Regimen

Editor's pick
AbbVie press release
11 January 2016